Almost 70 per cent of Canadians surveyed say child vaccines should be mandatory: poll
A new poll suggests nearly 70 per cent of Canadians support mandatory childhood vaccinations.
The Angus Reid Institute survey comes as a measles outbreak touches several provinces, primarily infecting unvaccinated infants, kids and teens.
The poll of almost 1,700 Canadians found 69 per cent of respondents between May 20 and 23 said proof of immunization should be required for kids to attend daycare and school.
That statistic was slightly lower in Alberta, at 60 per cent, but higher than the 48 per cent of Albertans who supported a mandate last year.
Last week, Ontario reported nearly 1,800 measles cases had emerged since the outbreak began in October. Alberta reported 628 cases on Wednesday.
The polling industry's professional body, the Canadian Research Insights Council, says online surveys cannot be assigned a margin of error because they do not randomly sample the population.
The poll found 37 per cent of respondents in Alberta said they had no confidence in their provincial government's response to measles, while 30 per cent said the same in Saskatchewan and 27 per cent said that in Ontario.
A Canadian Journal of Public Health article published in October 2024 found approximately 76 per cent of seven-year-olds were vaccinated against measles in 2023, down from just over 86 per cent in 2019.
This report by The Canadian Press was first published May, 29, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
2 hours ago
- Winnipeg Free Press
Getting the facts out on childhood vaccinations
Opinion As is the case with many instances involving polls, surveys and percentages, how one views this result is largely a matter of perception. Glass half-full, glass half-empty; that kind of thing. Many who read the survey released last week by the polling firm Angus Reid no doubt took encouragement from the revelation that nearly 70 per cent of Canadians support mandatory childhood vaccinations — a figure that likely reflects growing public unease at the recent rise in reported measles cases across the country. The poll, conducted online between May 20 and 24, found 69 per cent of the 1,700 people surveyed said proof of vaccination should be required for children to attend school or daycare. A similar survey last year showed 55 per cent in support of mandatory vaccination for kids attending school/daycare. Geoff Robins / The Canadian Press A dose of the measles, mumps, and rubella (MMR) vaccination. The increased support for a legislated vaccine requirement coincides, of course, with the sharp rise in reported measles cases — an increase attributed to declining vaccination rates and the loss of the so-called 'herd immunity' that had allowed the highly contagious disease to be largely eradicated after the MMR (measles/mumps/rubella) vaccine was introduced in the early 1970s. In recent years, vaccine skepticism fuelled by online misinformation and widely debunked conspiracy theories — and accelerated by broader resistance to mandated vaccination during the COVID-19 pandemic — has led to fewer parents seeking to have their children immunized against MMR. In 2023, vaccination rates in Canada were approximately 82 per cent for one dose and 76 per cent for the recommended two doses, significantly below the 95 per cent uptake required to maintain herd immunity. All of which helps to explain why in Canada, in 2025, there have been 2,755 new cases of measles (2,429 confirmed, 326 probable) reported as of May 24, spread across nine provincial/territorial jurisdictions — including Manitoba, which has recorded 76 cases (72 confirmed, four probable) this year. Tuesdays A weekly look at politics close to home and around the world. The outbreak — which has been mirrored in other countries, including the U.S., where vaccine uptake has waned — is unnecessary and could have been prevented. The MMR vaccine is safe, effective and proven, and does not — contrary to the myriad falsehoods spread online by misinformed conspiracy theorists — have any connection to autism or other negative childhood afflictions. So the good news, such as it is, is that an increasing number of Canadians seem inclined to support a vaccination requirement for kids attending schools and daycares — close-quarters environments in which exposure to contagious diseases such as measles could easily trigger an outbreak. But the glass-half-empty view of the situation is that despite the alarming rise in measles cases, nearly one-third of the population remains opposed to mandatory vaccination. Proof of vaccination for kids to attend school/daycare (except for those with a valid exemption) is currently only required in Ontario and New Brunswick, and given the high rate of resistance to mandated vaccination, there's very little likelihood such a measure would be imposed in Manitoba or other regions currently without one. In this province, figures from 2023 showed nearly 80 per cent of children were vaccinated against MMR by age two and 65 per cent fully immunized by age seven, significantly lower than the national average. And in the Southern Health region, the epicentre of Manitoba's current outbreak, vaccination uptake among seven-year-olds is just 53 per cent. Clearly, the province must do a better job of communicating the risks and benefits to those in need of reliable, factual information. Recent public-opinion poll numbers may be encouraging, but when it comes to limiting the spread of measles in Manitoba, the glass is concerningly tilting toward empty.
Cision Canada
5 hours ago
- Cision Canada
Bridging the Gap: Manulife Partners with Maven Clinic to Bring Women's and Family Health Services to Members Français
New partnership will help provide support and navigation for women, spanning fertility and family building, maternity and newborn care, parenting and pediatrics, and menopause and midlife TORONTO, June 5, 2025 /CNW/ - Manulife Canada is excited to announce it has partnered with Maven Clinic ®, the world's largest virtual clinic for women's and family health 1. This partnership will provide eligible Manulife Group Benefits plan members with unlimited access to Maven's award-winning digital programs for tailored support 2. Maven specializes in supporting women and families through some of their most important stages of life, including fertility, family building and planning; maternity and newborn care; parenting and pediatrics; and menopause and midlife. The need to prioritize women's health has never been more apparent. Research indicates narrowing gaps in women's health care could contribute as much as $1 trillion per year to the global economy by 2040 3. Globally, women spend 25 per cent more time in poor health compared to men, with nearly half of this health burden occurring during their prime working years—often limiting their ability to earn an income and support themselves and their families 4. In Canada, unmanaged menopause symptoms during critical career years (ages 40 to 55) cost the Canadian economy $3.5 billion annually and cause 1 in 10 women to leave the workforce 5. "Together with Maven, Manulife is not just responding to gaps in women's and family health—we're redefining what comprehensive support looks like during key life transitions like family planning and menopause," says Jennifer Foubert, Head of Product, Manulife Group Benefits. "We're proud to be the first insurance company in Canada to offer these important programs through Maven that will help our members access personalized and holistic support and navigation when they feel they need it most, wherever they are on their journey." Beginning this fall, Manulife Group Benefits plan members, whose employers enroll in Maven, will have 24/7 virtual access to Maven's platform, connecting them to a global network of providers across more than 30 specialties who speak more than 35 languages. While this is not an alternative for visiting in-person health care providers, with more than one in five Canadians without access to a primary care physician 6, Maven can help women and families navigate the Canadian healthcare system through its digital platform and help members find in-person care. Maven's diverse network of providers helps ensure that non-medical support is accessible and inclusive for individuals from all backgrounds. Plan members and their eligible dependants will benefit from unlimited access to virtual care, delivering high-quality, personalized support tailored to their unique health needs 2. "We are excited to partner with Manulife to help women and families receive comprehensive, personalized care," said Stephanie Glenn, Chief Commercial Officer at Maven Clinic. "As an organization, we set out to address the fragmented experiences women and families often face in health care through offering a holistic approach with tailored support, leading to better health outcomes and smoother journeys through life's critical phases. By expanding our global footprint with partners like Manulife, Maven is thrilled to deliver personalized guidance and assistance to Manulife members across Canada." Maven's offerings are built around four key pillars that most impact women's and family health: Fertility & Family Building: helping individuals and couples navigate their family-building journeys, including support for preconception and trying to conceive, fertility treatment like IVF and IUI, adoption, and surrogacy. Maternity & Newborn Care: extensive support during pregnancy, postpartum, and return to work, including access to virtual, non-medical consultation with participating OB-GYNs, doulas, lactation consultants, career coaches, and mental health providers. Maven also provides compassionate support for individuals experiencing loss. Parenting & Pediatrics: this program provides resources and consultations for parenting challenges and pediatric care, so families have access to the support they may need as their children grow. Menopause & Midlife Health: provides support through every phase of the menopause journey for women and midlife health support for men, including hormonal changes, mental health, sexual health, and overall well-being. Maven is a global leader in women's and family health, serving members across more than 175 countries. Beginning this fall, eligible Group Benefits Members and their eligible dependants will be able to access Maven through the Manulife Mobile app or plan member site. For more information, visit About Manulife Manulife Financial Corporation is a leading international financial services provider, helping our customers make their decisions easier and lives better. With our global headquarters in Toronto, Canada, we operate as Manulife across Canada, Asia, and Europe, and primarily as John Hancock in the United States, providing financial advice and insurance for individuals, groups and businesses. Through Manulife Wealth & Asset Management, we offer global investment, financial advice, and retirement plan services to individuals, institutions, and retirement plan members worldwide. At the end of 2024, we had more than 37,000 employees, over 109,000 agents, and thousands of distribution partners, serving over 36 million customers. We trade as 'MFC' on the Toronto, New York, and the Philippine stock exchanges, and under '945' in Hong Kong. Not all offerings are available in all jurisdictions. For additional information, please visit About Maven Maven is the world's largest virtual clinic for women and families on a mission to make healthcare work for all of us. Maven's award-winning digital programs provide clinical, emotional, and financial support all in one platform, spanning fertility & family building, maternity & newborn care, parenting & pediatrics, and menopause & midlife. More than 2,000 employers and health plans trust Maven's end-to-end platform to improve clinical outcomes, reduce healthcare costs, and provide equity in benefits programs. Recognized for innovation and industry leadership, Maven has been named to the Time 100 Most Influential Companies, CNBC Disruptor 50, Fast Company Most Innovative Companies, and FORTUNE Best Places to Work. Founded in 2014 by CEO Kate Ryder, Maven has raised more than $425 million in funding from top healthcare and technology investors including General Catalyst, Sequoia, Dragoneer Investment Group, Oak HC/FT, StepStone Group, Icon Ventures, and Lux Capital. To learn more about Maven, visit us at Maven is a registered trademark of Maven Clinic Co. All rights reserved. Maven Media Contact: Katy Geguchadze [email protected] _______________________ 1 Maven Clinic, Meet Maven, 2024 2 Available only to Group Benefits Members whose employers sign up to offer this support. 3 McKinsey Health Institute, 2024 4 McKinsey Health Institute, 2024 5 Menopause Foundation of Canada 6 OurCare. Primary Care Needs, 2024 SOURCE Manulife Financial Corporation
Cision Canada
7 hours ago
- Cision Canada
Biogen Disappointed by INESSS Recommendation on SKYCLARYS™ and its Impact on Quebec Patients with Friedreich Ataxia Français
TORONTO, June 5, 2025 /CNW/ - Biogen Canada Inc. is disappointed by INESSS's recommendation against listing SKYCLARYS™ (omaveloxolone), despite its therapeutic potential for individuals living with Friedreich ataxia (FA) — a community in urgent need of treatment options. A decision to not reimburse SKYCLARYS would leave individuals living with FA in Quebec without public access to the only approved treatment for this rare, progressive, and life-shortening neurodegenerative disease – despite a clear and ongoing medical need. 1 As the only approved treatment targeting disease progression, SKYCLARYS addresses a long-standing gap in care for Canadians living with FA, particularly in Quebec where a notable concentration of cases highlights the importance of equitable access. 2 "After years of research and failed trials with no approved treatments until now, the availability of a therapy with a demonstrated ability to slow disease progression and preserve mobility is profoundly meaningful for the Friedreich ataxia community, offering renewed hope and the possibility of managing the disease and care in FA. We remain committed to working with INESSS, government authorities, and clinicians to help ensure access to SKYCLARYS for eligible FA patients in Quebec and the rest of Canada," said Eric Tse, General Manager, Biogen Canada. SKYCLARYS was approved in March 2025 under Health Canada's Priority Review process as the first and only treatment in Canada to target the underlying mechanisms of FA in patients aged 16 and older. Canada's Drug Agency (CDA-AMC), which advises on drug reimbursement across Canada's public drug programs outside of Quebec, has issued a positive draft recommendation recognizing SKYCLARYS as an important therapeutic option, valued by patients, caregivers, and clinicians for its potential to improve quality of life and preserve function. 3 About SKYCLARYS™ (omaveloxolone) SKYCLARYS™ (omaveloxolone) is an oral, once-daily medication indicated for the treatment of Friedreich ataxia (FA) in adults and adolescents aged 16 years and older in the United States (U.S.), European Union and Canada. 4,5,6 SKYCLARYS received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA). 5 The European Commission granted Orphan Drug designation in Europe to SKYCLARYS for the treatment of FA. 6 In Canada, marketing authorization for SKYCLARYS was granted under the Health Canada Priority Review process. 7 Biogen continues to be dedicated to advancing research and development efforts to enhance the understanding of FA and improve patient outcomes. This includes an ongoing, open-label, Phase 1 study to evaluate the use of SKYCLARYS in in pediatric patients aged 2 to 15 years. More details can be found at About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment, to deliver long-term growth. Biogen has been proudly serving Canadian patients for more than 25 years. For information about Biogen Canada, please visit
